Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 8375429

Progress note on Japanese multicenter bromocriptine monotherapy.

S Kuno
View original source ↗Export metadata ↓

Abstract

The nationwide multicenter collaborative study for evaluating the monotherapy of Parkinson's disease with bromocriptine for a period of 5 years from 1986 was reviewed last year. The present report summarizes the follow-up in its 6th year: it includes 30 patients with Parkinson's disease who continued to receive bromocriptine monotherapy for 6 years and 66 patients who received bromocriptine-levodopa combination therapy during the same period. The mean daily dose of bromocriptine in the 6th year was about the same in the two groups (11.9 and 12.2 mg). In terms of Hoehn-Yahr's severity grade, severity increased in 20% of the patients undergoing bromocriptine monotherapy, whereas of the patients in the bromocriptine-levodopa combination group it was 45%. Wearing-off phenomenon was not seen in the bromocriptine monotherapy group. By contrast, 30% of the patients in the combination therapy group manifested this phenomenon which, when it occurred, invariably followed the administration of levodopa. Absence of the wearing-off phenomenon implies that bromocriptine has a direct protective action on degenerating substantia nigra.

Explore related subjects

BromocriptineDose-Response Relationship, DrugFollow-Up StudiesHumansJapanLevodopaLong-Term CareNeurologic ExaminationParkinson DiseaseClinical TrialComparative StudyJournal ArticleMulticenter StudyRandomized Controlled Trial

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Kuno. 1993. Progress note on Japanese multicenter bromocriptine monotherapy.. https://doi.org/10.1159/000118532

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4.

Cytochrome P450 (P450) 3A4, the major catalyst involved in human drug oxidation, displays substrate- and reaction-dependent homotropic and heterotropic cooperative behavior. Although several models have been proposed, these mainly rely on steady-state kinetics and do not provide information on the contribution of the individual steps of P450 catalytic cycle to the observed cooperativity. In this work, we focused on the kinetics of substrate binding, and the fluorescent properties of bromocriptine and alpha-naphthoflavone allowed analysis of an initial ligand-P450 3A4 interaction that does not cause a perturbation of the heme spectrum. The binding stoichiometry for bromocriptine was determined to be unity using isothermal titration calorimetry and equilibrium dialysis methods, suggesting that the ligand bound to the peripheral site during the initial encounter dissociates subsequently. A three-step substrate binding model is proposed, based on absorbance and fluorescence stopped-flow kinetic data and equilibrium binding data obtained with bromocriptine, and evaluated using kinetic modeling. The results are consistent with the substrate molecule binding at a site peripheral to the active site and subsequently moving toward the active site to bind to the heme and resulting in a low to high spin iron shift. The last step is attributed to a conformational change in the enzyme active site. The later steps of binding were shown to have rate constants comparable with the subsequent steps of the catalytic cycle. The P450 3A4 binding process is more complex than a two-state system, and the overlap of rates of some of the events with subsequent steps is proposed to underlie the observed cooperativity.

Bromocriptine↗
PubMed2006

[A cocaine-induced variant of the neuroleptic malignant syndrome. A case study].

In this article we discuss the case of a patient with schizophrenia who presented with the clinical symptoms ofcoma, fever and rigidity. Initially it was suspected that the patient had a neuroleptic malignant syndrome. Closer inspection revealed that the patient had recently used cocaine. It is known that cocaine can cause a variant of the neuroleptic malignant syndrome. The patient was treated with dantrolene sodium and bromocriptine in the Intensive Care Unit and made a complete recovery within four days.

Bromocriptine↗